CYP2C9 Poor Metabolizer Management
Critical High-Risk Medications Requiring Dose Adjustment
- The American College of Cardiology recommends reducing initial warfarin dose by 25-50% in CYP2C9 poor metabolizers to prevent severe and life-threatening bleeding episodes 3, 4
- CYP2C9 metabolizes the S-enantiomer of warfarin, which is 5 times more potent than the R-enantiomer 4
- For patients with CYP2C9 poor metabolizer genotypes (2/2, 3/3, 2/3), the American Heart Association suggests initiating CYP2C9 substrate medications at 50% of the standard starting dose and considering alternative therapies for drugs with narrow therapeutic indices 1, 2
- The American Academy of Neurology recommends reducing phenytoin maintenance doses by 31-52% in homozygous poor metabolizers (2/2, 3/3, 2/3) 1, 2, 3
- Siponimod is contraindicated in CYP2C93/3 poor metabolizers per FDA labeling 6, 7
Drug-Drug Interactions: Compounding Risk
- CYP2C9 poor metabolizers are at exponentially higher risk when exposed to CYP2C9 inhibitors 4, 7
- The American Heart Association recommends avoiding strong CYP2C9 inhibitors such as sulfamethoxazole/trimethoprim, metronidazole, and fluconazole in CYP2C9 poor metabolizers 4, 5, 8
Clinical Monitoring Algorithm
- The American College of Medical Genetics recommends confirming CYP2C9 genotype before initiating narrow therapeutic index drugs (warfarin, phenytoin) 1, 3
- For poor metabolizers (2/2, 3/3, 2/3), the National Institutes of Health suggests starting all CYP2C9 substrates at 50% standard dose and increasing monitoring frequency by 2-fold during titration 1, 3
Common Pitfalls to Avoid
- The American Medical Association advises against assuming absence of drug interactions means safety, as drug-drug interactions can convert intermediate metabolizers into phenotypic poor metabolizers 7
- African ancestry patients should be tested for CYP2C95, 6, 8, 11 alleles, which are not detected by standard panels but confer decreased function 3, 6, 7